Linked Life Data

16996847

Source:http://linkedlifedata.com/resource/pubmed/id/16996847

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2006-9-25
pubmed:abstractText
The WATCHMAN left atrial appendage occluder device (Atritech, Inc, Minneapolis, MN) is currently being tested in a Food and Drug Administration-approved clinical trial, the PROTECT AF trial, for patients who are diagnosed with paroxysmal, persistent, or permanent nonvalvular atrial fibrillation. However, rigorous screening and the study design have resulted in the exclusion of a large number of patients. Hence, the purpose of this study was to assess the potential utility of this device among those who were eligible but excluded for trial criteria and the reasons for exclusion.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1097-6744
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
152
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
720-3
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Potential applicability and utilization of left atrial appendage occlusion devices in patients with atrial fibrillation.
pubmed:affiliation
Section of Internal Medicine and Cadiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA. fountain.rebecca@mayo.edu
pubmed:publicationType
Journal Article